Clinical Trial Update: Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study of stereotactic hypofractionated radioablation (HYDRA) treatment for laryngeal cancer, currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Laryngeal Cancer
• Squamous Cell Carcinoma of the Larynx

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Malignant Neoplasms of Respiratory and Intrathoracic Organs, Squamous Cell Carcinoma of the Larynx | Phase 1 | Status: RECRUITING